Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

224 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-05-18

Study Completion Date

2021-07-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the effect of adalimumab on health outcomes in participants with rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis

NCT01114880

Ankylosing Spondylitis

COMPLETED PHASE3

Study of Adalimumab in Patients With Axial Spondyloarthritis

NCT00939003

Axial Spondyloarthritis

COMPLETED PHASE3

Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients

NCT04875299

Ankylosing Spondylitis

UNKNOWN

Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China

NCT02668640

Rheumatoid Arthritis

COMPLETED

Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan

NCT02616380

Rheumatoid Arthritis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ankylosing Spondylitis (AS) Psoriasis Rheumatoid Arthritis (RA)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with Rheumatoid Arthritis (RA)

This group/ cohort includes participants with RA.

No interventions assigned to this group

Participants with Plaque Psoriasis (Ps)

This group/ cohort includes participants with Ps.

No interventions assigned to this group

Participants with Ankylosing spondylitis (AS)

This group/ cohort includes participants with AS.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants with a diagnosis of rheumatoid arthritis, ankylosing spondylitis or plaque psoriasis
* Decision to initiate Humira® treatment in accordance with routine medical practice and in compliance with eligibility for adalimumab based on the local label
* Prior to any study-specific procedures, participant has voluntarily signed the authorization (or informed consent where applicable) to disclose and use anonymized personal health information after participate in this research.

Exclusion Criteria

* Inadequate response to previous standard treatment with anti-tumor necrosis factor (TNF) biological agent according to the physician's clinical judgment.
* Participant has been treated with adalimumab within 70 days (five half-lives) prior to the Baseline Visit.
* Participants discontinued due to adverse drug reaction of previous adalimumab treatment.
* Participants who fulfill any of the contraindications as per adalimumab label in China.
* Participants, who in the clinician's view, may not be able to comply with the study requirements.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No